Primary immunodeficiency medical therapy

Jump to navigation Jump to search

Primary immunodeficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Primary immunodeficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Primary immunodeficiency medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary immunodeficiency medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary immunodeficiency medical therapy

CDC on Primary immunodeficiency medical therapy

Primary immunodeficiency medical therapy in the news

Blogs on Primary immunodeficiency medical therapy

Directions to Hospitals Treating Primary immunodeficiency

Risk calculators and risk factors for Primary immunodeficiency medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Primary immunodeficiency is generally treated by immunotherapy either through intravenous infusions of immunoglobulin (IVIG) in an effort to induce passive immunity (Immunotherapy is not indicated for those who are IgA deficient). A new subcutaneous treatment (SC-Ig) was recently approved by the FDA, which is especially recommended in cases of severe adverse effects to the IV-Ig treatment or with individuals with poor venous access. Persons with immunodeficiencies are very vulnerable to opportunistic infections, and the use of antimicrobial agents, such as antibiotics and antifungals, is often required. One of the future prospects in the treatment primary immunodeficiency is gene therapy. However, this form of treatment is in its infancy, and the feasibility and long-term complications of gene therapy are not known.

References